Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients.
borderline personality disorder
naltrexone
neuropeptide
opioid receptor
psychopharmacology
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
05
05
2021
received:
14
10
2020
accepted:
06
05
2021
pubmed:
25
5
2021
medline:
16
3
2022
entrez:
24
5
2021
Statut:
ppublish
Résumé
The endogenous opioid system is assumed to be involved in the pathophysiology of borderline personality disorder (BPD), and opioid antagonists may improve core features of BPD. The aim of this retrospective chart analysis was to evaluate the relative contribution of the opioid antagonist naltrexone and other psychotropic drugs in the improvement of overall symptomatology in BPD. One hundred sixty-one inpatients with BPD treated between January 2010 and October 2013 were classified as either treatment responders or non-responders. Treatment responders were defined as subjects with significant improvements in four or more symptoms from a defined symptom list. The relative contribution of all psychotropic drugs to improvement of BPD symptomatology was assessed by means of a stepwise logistic regression. None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio [OR] 43.2, p ≤ 0.0001). Patients treated with naltrexone (N = 55, 34%) recovered significantly more often. Higher doses of naltrexone were more effective (OR 791.8, p ≤ 0.0001) than lower doses (OR 26.6, p ≤ 0.0001); however, even low-dose treatment was better than any other pharmacological treatment. Naltrexone was associated with improvement in BPD in a dose-dependent manner. The present study provides additional evidence that dysregulation of the endogenous opioid system is implicated in the pathophysiology of BPD symptoms.
Substances chimiques
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2800Informations de copyright
© 2021 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons Ltd.
Références
Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., Bayliss, S., Roberts, T., & Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technology Assessment (Winchester, England), 11(6), iii-iv, 1-85.
Anderson, G. (2020). Pathoetiology and pathophysiology of borderline personality: Role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 98, 109782. https://doi.org/10.1016/j.pnpbp.2019.109782
Anton, R. F., Pettinati, H., Zweben, A., Kranzler, H. R., Johnson, B., Bohn, M. J., McCaul, M. E., Anthenelli, R., Salloum, I., Galloway, G., Garbutt, J., Swift, R., Gastfriend, D., Kallio, A., & Karhuvaara, S. (2004). A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 24(4), 421-428.
Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010). Borderline personality disorder: A dysregulation of the endogenous opioid system? Psychological Review, 117(2), 623-636. https://doi.org/10.1037/a0018095
Barnicot, K., Katsakou, C., Bhatti, N., Savill, M., Fearns, N., & Priebe, S. (2012). Factors predicting the outcome of psychotherapy for borderline personality disorder: A systematic review. Clinical Psychology Review, 32(5), 400-412. https://doi.org/10.1016/j.cpr.2012.04.004
Bellino, S., Bozzatello, P., & Bogetto, F. (2015). Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: Predictors of response. Psychiatry Research, 226(1), 284-288. https://doi.org/10.1016/j.psychres.2014.12.064
Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., & Schmahl, C. G. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder. The Journal of Clinical Psychiatry, 60(9), 598-603.
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research, 1314, 44-55. https://doi.org/10.1016/j.brainres.2009.08.062
Dell'Osso, B., Berlin, H. A., Serati, M., & Altamura, A. C. (2010). Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology, 61(4), 169-179. https://doi.org/10.1159/000297734
Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004). Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcoholism: Clinical & Experimental Research, 28(9), 1362-1370.
Dubovsky, A. N., & Kiefer, M. M. (2014). Borderline personality disorder in the primary care setting. Medical Clinics of North America, 98(5), 1049-1064. https://doi.org/10.1016/j.mcna.2014.06.005
Gunderson, J. G., & Lyons-Ruth, K. (2008). BPD's interpersonal hypersensitivity phenotype: A gene-environment-developmental model. Journal of Personality Disorders, 22(1), 22-41. https://doi.org/10.1521/pedi.2008.22.1.22
Herpertz, S. C., & Bertsch, K. (2015). A new perspective on the pathophysiology of borderline personality disorder: A model of the role of oxytocin. The American Journal of Psychiatry, 172(9), 840-851. https://doi.org/10.1176/appi.ajp.2015.15020216
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008). Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial. The American Journal of Psychiatry, 165(11), 1442-1448. https://doi.org/10.1176/appi.ajp.2008.08020304
Kalin, N. H., Shelton, S. E., & Lynn, D. E. (1995). Opiate systems in mother and infant primates coordinate intimate contact during reunion. Psychoneuroendocrinology, 20(7), 735-742. https://doi.org/10.1016/0306-4530(95)00023-2
Karkhanis, A., Holleran, K. M., & Jones, S. R. (2017). Dynorphin/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction. International Review of Neurobiology, 136, 53-88. https://doi.org/10.1016/bs.irn.2017.08.001
Koenigsberg, H. W., Harvey, P. D., Mitropoulou, V., New, A. S., Goodman, M., Silverman, J., Serby, M., Schopick, F., & Siever, L. J. (2001). Are the interpersonal and identity disturbances in the borderline personality disorder criteria linked to the traits of affective instability and impulsivity? Journal of Personality Disorders, 15(4), 358-370. https://doi.org/10.1521/pedi.15.4.358.19181
Kröger, C., Harbeck, S., Rickert, I., Wollburg, E., Gersch, K., Armbrust, M., & Kliem, S. (2013). Remission, response und deren prädiktion nach einer dialektisch-behavioralen therapie der borderline-persönlichkeitsstörung im stationären setting. Zeitschrift für Klinische Psychologie und Psychotherapie, 42(1), 45-54. https://doi.org/10.1026/1616-3443/a000185
Marrazzi, M. A., Bacon, J. P., Kinzie, J., & Luby, E. D. (1995). Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. International Clinical Psychopharmacology, 10(3), 163-172.
Martín-Blanco, A., Ferrer, M., Soler, J., Arranz, M. J., Vega, D., Calvo, N., Elices, M., Sanchez-Mora, C., García-Martinez, I., Salazar, J., Carmona, C., Bauzà, J., Prat, M., Pérez, V., & Pascual, J. C. (2016). The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 266(4), 307-316. https://doi.org/10.1007/s00406-015-0612-2
Martín-Blanco, A., Patrizi, B., Soler, J., Gasol, X., Elices, M., Gasol, M., Carmona, C., & Pascual, J. C. (2017). Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder. International Clinical Psychopharmacology, 32(4), 231-234. https://doi.org/10.1097/YIC.0000000000000170
McGee, M. D. (1997). Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry, 58(1), 32-33.
Moghaddas, A., Dianatkhah, M., Ghaffari, S., & Ghaeli, P. (2017). The potential role of naltrexone in borderline personality disorder. Iranian Journal of Psychiatry, 12(2), 142-146.
Narayanan, S., Lam, H., Christian, L., Levine, M. S., Grandy, D., Rubinstein, M., & Maidment, N. T. (2004). Endogenous opioids mediate basal hedonic tone independent of dopamine D-1 or D-2 receptor activation. Neuroscience, 124(1), 241-246. https://doi.org/10.1016/j.neuroscience.2003.11.011
National Collaborating Centre for Mental Health. (2009). Borderline personality disorder: Treatment and management. British Psychological Society.
National Health Medical Research Council. (2013). Clinical practice guideline for the management of borderline personality disorder. National Health and Medical Research Council.
Panksepp, J., Herman, B., Conner, R., Bishop, P., & Scott, J. P. (1978). The biology of social attachments: Opiates alleviate separation distress. Biological Psychiatry, 13(5), 607-618.
Prossin, A. R., Love, T. M., Koeppe, R. A., Zubieta, J.-K., & Silk, K. R. (2010). Dysregulation of regional endogenous opioid function in borderline personality disorder. The American Journal of Psychiatry, 167(8), 925-933. https://doi.org/10.1176/appi.ajp.2010.09091348
Roth, A. S., Ostroff, R. B., & Hoffman, R. E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour:An open-label trial. The Journal of Clinical Psychiatry, 57(6), 233-237.
Roth-Deri, I., Green-Sadan, T., & Yadid, G. (2008). β-Endorphin and drug-induced reward and reinforcement. Progress in Neurobiology, 86(1), 1-21. https://doi.org/10.1016/j.pneurobio.2008.06.003
Sanislow, C. A., Grilo, C. M., Morey, L. C., Bender, D. S., Skodol, A. E., Gunderson, J. G., Shea, M. T., Stout, R. L., Zanarini, M. C., & McGlashan, T. H. (2002). Confirmatory factor analysis of DSM-IV criteria for borderline personality disorder: Findings from the collaborative longitudinal personality disorders study. The American Journal of Psychiatry, 159(2), 284-290. https://doi.org/10.1176/appi.ajp.159.2.284
Schmahl, C., Greffrath, W., Baumgärtner, U., Schlereth, T., Magerl, W., Philipsen, A., Lieb, K., Bohus, M., & Treede, R.-D. (2004). Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: Laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain, 110(1-2), 470-479. https://doi.org/10.1016/j.pain.2004.04.035
Schwarze, C. E., Mobascher, A., Pallasch, B., Hoppe, G., Kurz, M., Hellhammer, D. H., & Lieb, K. (2013). Prenatal adversity: A risk factor in borderline personality disorder? Psychological Medicine, 43(6), 1279-1291. https://doi.org/10.1017/S0033291712002140
Sonne, S., Rubey, R., Brady, K., Malcolm, R., & Morris, T. (1996). Naltrexone treatment of self-injurious thoughts and behaviors. The Journal of Nervous and Mental Disease, 184(3), 192-195.
Stanley, B., Sher, L., Wilson, S., Ekman, R., Huang, Y.-y., & Mann, J. J. (2010). Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. Journal of Affective Disorders, 124(1-2), 134-140. https://doi.org/10.1016/j.jad.2009.10.028
Stanley, B., & Siever, L. J. (2010). The interpersonal dimension of borderline personality disorder: Toward a neuropeptide model. Ajp, 167(1), 24-39. https://doi.org/10.1176/appi.ajp.2009.09050744
Stoffers, J. M., & Lieb, K. (2015). Pharmacotherapy for borderline personality disorder-current evidence and recent trends. Current Psychiatry Reports, 17(1), 534. https://doi.org/10.1007/s11920-014-0534-0
Streeton, C., & Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism (Oxford, Oxfordshire), 36(6), 544-552.
Symons, F. J., Thompson, A., & Rodriguez, M. C. (2004). Self-injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews, 10(3), 193-200. https://doi.org/10.1002/mrdd.20031
The National Institute for Health and Care Excellence. (2018). 2018 surveillance of personality disorders (NICE guidelines CG77 and CG78). The National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg78/resources/2018-surveillance-of.personality-disorders-nice-guidelines-cg77-and-cg78-pdf-6358811143669
Timäus, C., Meiser, M., Bandelow, B., Engel, K. R., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019). Pharmacotherapy of borderline personality disorder: What has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry, 19(1), 393. https://doi.org/10.1186/s12888-019-2377-z
Widiger, T. A., & Weissman, M. M. (1991). Epidemiology of borderline personality disorder. Hospital & Community Psychiatry, 42(10), 1015-1021. https://doi.org/10.1176/ps.42.10.1015
World Health Organization. (1992). The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. World Health Organization.
Yen, S., Johnson, J., Costello, E., & Simpson, E. B. (2009). A 5-day dialectical behavior therapy partial hospital program for women with borderline personality disorder: Predictors of outcome from a 3-month follow-up study. Journal of Psychiatric Practice, 15(3), 173-182. https://doi.org/10.1097/01.pra.0000351877.45260.70
Zanarini, M. C., Frankenburg, F. R., Reich, D. B., Harned, A. L., & Fitzmaurice, G. M. (2015). Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. Journal of Clinical Psychopharmacology, 35(1), 63-67. https://doi.org/10.1097/JCP.0000000000000232
Zubieta, J.-K., Ketter, T. A., Bueller, J. A., Xu, Y., Kilbourn, M. R., Young, E. A., & Koeppe, R. A. (2003). Regulation of human affective responses by anterior cingulate and limbic µ-opioid neurotransmission. Archives of General Psychiatry, 60(11), 1145-1153. https://doi.org/10.1001/archpsyc.60.11.1145